Entheon Biomedical Corp
Entheon Biomedical Corp. operates as a biotechnology research and development company. The company develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Entheon Biomedical Corp (ENTBF) - Net Assets
Latest net assets as of March 2025: $436.14K USD
Based on the latest financial reports, Entheon Biomedical Corp (ENTBF) has net assets worth $436.14K USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($452.26K) and total liabilities ($16.12K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $436.14K |
| % of Total Assets | 96.44% |
| Annual Growth Rate | -12.62% |
| 5-Year Change | -96.12% |
| 10-Year Change | N/A |
| Growth Volatility | 154.48 |
Entheon Biomedical Corp - Net Assets Trend (2018–2025)
This chart illustrates how Entheon Biomedical Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Entheon Biomedical Corp (2018–2025)
The table below shows the annual net assets of Entheon Biomedical Corp from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $145.33K | -53.97% |
| 2024-03-31 | $315.75K | -48.62% |
| 2023-03-31 | $614.57K | -93.21% |
| 2022-03-31 | $9.05 Million | +141.66% |
| 2021-03-31 | $3.74 Million | +121.13% |
| 2020-03-31 | $1.69 Million | -6.12% |
| 2019-03-31 | $1.80 Million | +382.62% |
| 2018-03-31 | $373.76K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Entheon Biomedical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2059795600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $21.07 Million | 14498.28% |
| Total Equity | $145.33K | 100.00% |
Entheon Biomedical Corp Competitors by Market Cap
The table below lists competitors of Entheon Biomedical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
$998.05K |
|
SRIVARU Holding Limited
PINK:SVUHF
|
$998.48K |
|
OSHKOSH
BE:OK3
|
$998.62K |
|
STATE STREET - Dusseldorf Stock Exchang
DU:ZYA
|
$998.66K |
|
Pharmadrug Inc
PINK:LMLLF
|
$996.23K |
|
Tie Holding NV
F:TJH7
|
$995.84K |
|
ALPHA MOS INH.EO 020
F:0MV
|
$995.82K |
|
d'Alba Global
KO:483650
|
$995.62K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entheon Biomedical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 315,751 to 145,328, a change of -170,423 (-54.0%).
- Net loss of 317,923 reduced equity.
- Other factors increased equity by 147,500.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-317.92K | -218.76% |
| Other Changes | $147.50K | +101.49% |
| Total Change | $- | -53.97% |
Book Value vs Market Value Analysis
This analysis compares Entheon Biomedical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.96x to 5.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | $0.09 | $0.09 | x |
| 2019-03-31 | $0.30 | $0.09 | x |
| 2020-03-31 | $0.28 | $0.09 | x |
| 2021-03-31 | $0.09 | $0.09 | x |
| 2022-03-31 | $0.15 | $0.09 | x |
| 2023-03-31 | $0.01 | $0.09 | x |
| 2024-03-31 | $0.05 | $0.09 | x |
| 2025-03-31 | $0.02 | $0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entheon Biomedical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -218.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.27x
- Recent ROE (-218.76%) is above the historical average (-246.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -38.79% | 0.00% | 0.00x | 1.50x | $-182.36K |
| 2019 | -8.73% | 0.00% | 0.00x | 1.02x | $-337.92K |
| 2020 | -8.67% | 0.00% | 0.00x | 1.02x | $-316.14K |
| 2021 | -117.00% | 0.00% | 0.00x | 1.19x | $-4.76 Million |
| 2022 | -98.19% | -41008.56% | 0.00x | 1.10x | $-9.79 Million |
| 2023 | -1386.45% | -4492.23% | 0.25x | 1.25x | $-8.58 Million |
| 2024 | -95.01% | -119.85% | 0.62x | 1.27x | $-331.58K |
| 2025 | -218.76% | 0.00% | 0.00x | 1.27x | $-332.46K |
Industry Comparison
This section compares Entheon Biomedical Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entheon Biomedical Corp (ENTBF) | $436.14K | -38.79% | 0.04x | $997.84K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |